SCHEMBL8934541

SCHEMBL8934541

CCc1c[nH]c(=O)c2ccc(OC3CCN(C)CC3)c(F)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.39
TDO2 P48775 1/20 0.37
HTR1A P08908 1/20 0.37
HRH1 P35367 4/20 0.36
CCR3 P51677 2/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TIPARP Q7Z3E1 1/20 0.34
ALK Q9UM73 1/20 0.33
LRRK2 Q5S007 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
USP1 O94782 1/20 0.33
USP8 P40818 1/20 0.33
OTUB1 Q96FW1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937197 0.90 DRD2 (0.42) HTR1AHRH1CCR3MAOAMAOB
SCHEMBL8937187 0.90 HRH1 (0.39) TDO2HTR1AHRH1CCR3
SCHEMBL8937200 0.89 MAOA (0.43) HTR1AHRH1CCR3MAOAMAOB
SCHEMBL8938566 0.87 ROCK1 (0.35) BRD4HTR1AHRH1CCR3
SCHEMBL8937203 0.87 HTR1A (0.37) HTR1AHRH1CCR3MAOAMAOB
SCHEMBL8937201 0.86 HRH1 (0.42) HTR1AHRH1CCR3
SCHEMBL8934493 0.86 MAOA (0.39) BRD4TDO2HRH1CCR3MAOA
SCHEMBL8934431 0.86 ROCK1 (0.41) TDO2HTR1AHRH1TIPARP
SCHEMBL8939065 0.86 HTR1A (0.37) HTR1AHRH1CCR3MAOAMAOB
SCHEMBL8937242 0.85 OPRL1 (0.40) HTR1AHRH1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 BRD4 1640/4885TDO2 4611/4885HTR1A 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.